Lista de obras - Nicola Gianotti - Dominio Público Uruguay

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

article

Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV.

artículo científico publicado en 2017

Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens

artículo científico publicado en 2013

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

artículo científico publicado en 2019

Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV-infected patients with virological suppression

artículo científico publicado en 2017

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

article by Antonella d'Arminio Monforte et al published April 2018 in HIV Clinical Trials

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting

artículo científico publicado en 2014

Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting

artículo científico publicado en 2013

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

artículo científico publicado en 2017

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

artículo científico publicado en 2009

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

artículo científico publicado en 2016

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients

artículo científico publicado en 2017

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

artículo científico publicado en 2017

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

artículo científico publicado en 2020

Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

article

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

artículo científico publicado en 2010

Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens

artículo científico publicado en 2019

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir

artículo científico publicado en 2013

Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection

artículo científico publicado en 2011

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score

artículo científico publicado en 2011

Nested polymerase chain reaction for diagnosis, and monitoring treatment response in AIDS patients with tuberculous meningitis ⬇️

artículo científico publicado el 1 de agosto de 1995

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

artículo científico publicado en 2010

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

artículo científico publicado en 2017

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

article

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort

artículo científico publicado en 2016

Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2)

scientific article published on 04 March 2020

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen

article

Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy

artículo científico publicado en 2014

Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation

artículo científico publicado en 2007

Lista de obras de Nicola Gianotti

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV.

Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV-infected patients with virological suppression

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting

Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir

Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score

Nested polymerase chain reaction for diagnosis, and monitoring treatment response in AIDS patients with tuberculous meningitis ⬇️

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort

Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2)

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen

Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy

Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation